首页
外语
计算机
考研
公务员
职业资格
财经
工程
司法
医学
专升本
自考
实用职业技能
登录
外语
The Embarrassing Pharmaceutical Industry The image of drug industry The drug industry’s image problems are beginning to hurt
The Embarrassing Pharmaceutical Industry The image of drug industry The drug industry’s image problems are beginning to hurt
admin
2010-06-11
50
问题
The Embarrassing Pharmaceutical Industry
The image of drug industry
The drug industry’s image problems are beginning to hurt pharmaceutical companies where it matters most-- at the bottom line.
A year after Merck’s withdrawal of its arthritis medicine Vioxx led to an industry wide credibility crisis, the Food and Drug Administration is blocking new medicines that might previously have passed muster. Doctors are writing fewer prescriptions for antidepressants and other drugs whose safety has been challenged, like hormone replacement therapies for women in menopause.
Meanwhile, insurers and some states are taking advantage of the backlash against the industry to try shifting patients to older, generic drugs, arguing that they work as well as newer and more expensive branded medicines. Overall, prescriptions continue to rise slightly, but an increasing share of prescriptions are going to generic drugs. Also, consumers seem to be less responsive to aggressive drug marketing.
The industry lost trust
"A lot of the demand that the industry has created over the years has been through promotion, and for that promotion to be effective, there has to be trust," said Richard Evans, an analyst covering drug stocks at Sanford C. Bernstein and Company. "That trust has been lost."
In the background, new competitors are forcing the old-line drug giants to struggle to keep pace. Biotechnology companies like Genentech are taking the lead in finding new treatments for cancer, a promising and lucrative field.
Executives of the major drug companies say they expect public scrutiny in the wake of problems with Vioxx and other drugs. But they say they are concerned that consumer mistrust has led to unrealistic expectations about drug safety and risks, stunting the development of new medicines.
"I think there is an overall unreasonable expectation right now that there is such a thing as a risk free drug," said Sidney Taurel, chief executive of Eli Lilly & Company.
The major drug makers remain highly profitable. But at some, including Pfizer and Merck, the largest and third-largest American companies in terms of revenue, sales are stagnant and profits are failing, leading to layoffs and-- for the first time in years-- cuts in research budgets. The drug industry, which is dominated by companies based in this country, is hardly in a full-blown crisis, and layoffs are occurring mainly on the margins of its work force. Pfizer alone will make about $ 8 billion in profit this year, on sales of about $ 51 billion, and invest more than $ 7 billion in research and development although the company’s research spending fell 6 percent in the third quarter of 2005 compared with the same period in 2004, and Pfizer expects it to stay flat or decline in the coming years. Overall, the industry spends more than $ 30 billion annually on research and development.
But for the companies, and for patients who are counting on industry research to produce new treatments for diseases like rheumatoid arthritis and diabetes, these are trying times. Wall Street has also taken notice of the industry’s woes. Shares of Pfizer are near their lowest levels since 1997, closing Friday at $ 22.43, and a broad index of drug stocks has fallen 25 percent in five years. In contrast, shares of biotechnology companies are soaring.
Without new drugs to promote as patents expire, and with the bar set so high by the blockbusters of the last decade, the old-line companies have depended on stopgap measures to protect sales, like reformulating existing drugs so they can be taken once a week instead of once daily. At the same time, they have used consumer advertising to drive patient demand. But those strategies appear to be losing their effectiveness, as consumers become more skeptical and insurers rebel against high prices for drugs that are not therapeutic breakthroughs.
Public opinions on drug price and quality
"Is the public more cynical? Yes," said Dr. John LaMattina, Pfizer’s president of global research. "There’s a perception that we don’t bring much to the party."
Consumers have been irritated for years by drug prices in the United States, which are higher than in other industrialized countries. But anger at the industry reached a new pitch in the summer of 2004, with the disclosure that several companies had suppressed the results of clinical trials that showed an increased risk of suicidal thoughts by people taking antidepressants.
Then Merck stopped selling Vioxx after a clinical trial showed that the painkiller increased the risk of heart attacks and strokes. Internal Merck documents showed that company executives and scientists were concerned about Vioxx as early as 1997 but rejected plans to conduct a study of the heart risks. Merck has said it acted properly in its handling of Vioxx studies.
A poll last month showed that only 9 percent of Americans believed drug companies were generally honest, down from 14 percent in 2004. In contrast, 34 percent of people said they trusted banks, and 39 percent trusted supermarkets.
"We’ve created an impression with the American public that when a drug is approved, it’s perfectly safe," said Billy Tauzin, president of the Pharmaceutical Research and Manufacturers of America, a lobbying organization for brand-name drug companies. "We have not done a good job about educating the patients of America that all drugs come with significant side effects."
Mr. Tauzin said the industry was "beginning to make progress and turn. things around." He said it was addressing its image crisis by being more careful with its advertising, by pledging more disclosure of clinical trial results and by working to make low-priced drugs available to poor and uninsured Americans.
The industry is counting on research into genetics and the basic mechanisms of cellular behavior to produce genuine breakthroughs in treatment for diseases like diabetes. But executives and outside analysts warn that such a revival will probably not happen before the end of this decade at the earliest.
"Early stage pipelines are very, very full in a lot of companies," said Mr. Taurel of Lilly, which is the sixth-largest American drug company, and one of the few that is substantially increasing research spending. "But it will take some time for all of these products to reach the marketplace."
Further, the companies are victims of their own success in some important drug categories, such as diabetes, where existing treatments work well enough to discourage the F. D. A. from approving new drugs if they have significant side effects.
The unsatisfactory new drugs
Last month, Bristol-Myers Squibb said it might stop research on Pargluva, a new diabetes drug, because the F.D.A. had said it would not approve it without additional clinical trials that might take up to five years.
Pargluva is not the only drug the federal regulatory agency has blocked recently. In September, the agency turned down two drugs from Pfizer, a painkiller and an osteoporosis(骨质疏松症) medicine. Last month, it rejected Johnson & Johnson’s bid to market a drug to treat premature ejaculation.
Before the Vioxx withdrawal, the F.D. A. would probably have approved Pargluva, and the other drugs would have had a better chance, said Les Funtleyder, an analyst with Miller Tabak. Now the agency is taking longer to review drugs and weighing side effects more seriously, he said.
"The F. D. A. has changed," Mr. Funtleyder said. "Nobody wants to be on ’60 Minutes’ being asked about why a dangerous drug was approved," he added.
Doctors recommended the use of hormone replacement therapies.
选项
A、Y
B、N
C、NG
答案
B
解析
文章第二段提到“hormone replacement therapies for women in menopause”意思是医生建议荷尔蒙替代疗法来治疗更年期的疾病。因此题干说的是错误的。
转载请注明原文地址:https://kaotiyun.com/show/6FKK777K
0
大学英语六级
相关试题推荐
Mostpeopledon’tenjoyfacingthedifficultsituationsthatsometimesoccurwithcoworkersintheworkplace.Suchsituationsma
Whichofthefollowingdoes"labormarketproblems"(Line1,Para.1)referto?Whichofthefollowingproposalsbestresponds
Therearetwobasicwaystoseegrowth:Oneasaproduct,theotherasaprocess.Peoplehave【B1】viewedpersonalgrowthasanex
A、Unemployment.B、Familybreakup.C、Mentalproblems.D、Drinking.BW:Tony,whoarethestreetpeople?Howdidtheygettobeliv
Wildducksandothermigratory(迁移的)birdscouldbeimportantcarriersofdeadlybirdflu,researcherssay.Evenso,theinfecti
A、Theyhavetogotoworkearlyinthemorning.B、Theyhaveareputationforgoodhumor.C、Theyhavetodoadifficultjob.D、Th
TheEnglish【B1】______settlementsinNorthAmericabeganinthe17thcenturywhenWesternEuropewas【B2】______greatchanges
A、Conservative.B、Feminist.C、Housewife.D、Politician.A这位妇女居然反对妇女有辅选权,证明她是一位保守主义分子,选A。
Inadditiontohistheoryofcolour,Newtondevelopedatheoryofhowlighttravels.Thisisknownasthecorpuscular(微粒子的)the
随机试题
The______goalofthebookistohelpbridgethegapbetweenresearchandteaching,particularlythegapbetweenresearchersan
女性,32岁,反复发热37.5~38℃左右1个月,伴关节肌肉酸痛就诊,体检:轻度贫血,心界不大,心率90次分,心尖区有收缩期吹风样杂音Ⅲ级,并有收缩中期喀喇音。诊断为风湿性心脏病,二尖瓣关闭不全,发热待查。本例拟给予心内膜炎诊断性治疗,对抗生素反应良
下列法律渊源属于行政法规范畴的是()。
某公路隧道位于设计基本地震动峰值加速度0.20g的地区,其隧道边缘距离主断裂边缘的距离应大于()m。
“十一五”期间,我国住宅建筑和公共建筑严格执行节能()的标准。
企业领导系统的核心是()。
【2010年】处于初创阶段的公司,一般不宜采用的股利分配政策有()。
放学后,15岁的李某与同学王某在酒店和朋友聚餐,在喝完从酒店买的白酒后,李某与王某发生了争执,李某拿起酒瓶击中王某的头部,致使王某成为植物人。此次伤害事件中,下列说法正确的是()。
为什么说“三个代表”是我们党的立党之本、执政之基、力量之源?
A公司发行在外的零息债券剩余期限为一年,面值为100元,当前价格为96.15元,若A公司为全权益公司,它的贝塔系数为1.2,公司的目标负债一权益比为0.3,市场组合的期望收益率为11%,同期国债的收益率为3.5%,税率为35%,求公司的加权平均资本成本。
最新回复
(
0
)